BIAF (bioAffinity Technologies) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIAF bioAffinity Technologies Inc BIAF
44 GF Score
Price $0.68
GF Value $4.16
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies Net Loan?

Net Loan only applies to banks and insurance companies.

BIAF
44GF Score
bioAffinity Technologies Inc BIAF
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.68 is trading 83.7% below its estimated GF Value™ of $4.16. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

  • Net Loan:
  • GF Value™: $4.16 vs. price of $0.68 (83.7% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


bioAffinity Technologies Business Description

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAF

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price
$4.16
GF Value